Zacks Research Upgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Strong-Buy

Supernus Pharmaceuticals (NASDAQ:SUPN) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

A number of other equities analysts have also issued reports on SUPN. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Cantor Fitzgerald boosted their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, July 9th. Finally, Wall Street Zen lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.83.

Supernus Pharmaceuticals Price Performance

Shares of SUPN opened at $47.64 on Thursday. The firm has a market capitalization of $2.77 billion, a PE ratio of -24.81, a price-to-earnings-growth ratio of 0.76 and a beta of 0.56. Supernus Pharmaceuticals has a 1-year low of $40.26 and a 1-year high of $59.68. The company’s fifty day moving average price is $46.17 and its 200-day moving average price is $48.93.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Sit Investment Associates Inc. raised its stake in Supernus Pharmaceuticals by 0.4% in the fourth quarter. Sit Investment Associates Inc. now owns 65,200 shares of the specialty pharmaceutical company’s stock valued at $3,240,000 after buying an additional 250 shares in the last quarter. Summit Global Investments boosted its position in shares of Supernus Pharmaceuticals by 6.1% during the 1st quarter. Summit Global Investments now owns 4,436 shares of the specialty pharmaceutical company’s stock worth $229,000 after acquiring an additional 256 shares in the last quarter. Maryland State Retirement & Pension System boosted its position in shares of Supernus Pharmaceuticals by 3.6% during the 4th quarter. Maryland State Retirement & Pension System now owns 8,351 shares of the specialty pharmaceutical company’s stock worth $415,000 after acquiring an additional 290 shares in the last quarter. SummitTX Capital L.P. increased its holdings in shares of Supernus Pharmaceuticals by 2.7% in the 4th quarter. SummitTX Capital L.P. now owns 11,670 shares of the specialty pharmaceutical company’s stock valued at $580,000 after acquiring an additional 303 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Supernus Pharmaceuticals by 2.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 14,548 shares of the specialty pharmaceutical company’s stock valued at $752,000 after acquiring an additional 321 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.